Cell-Based Assays Products & Reviews

We offer extensive Antibody Functional Characterization Services, focusing on both Fab-based target binding and Fc-mediated effector functions. Our assays analyze mechanisms like Neutralization, ADCC, CDC, and ADCP, leveraging advanced platforms to select promising therapeutic candidates.

Creative Biolabs delivers an end-to-end CAR-T development pathway—from target/scFv discovery, CAR design and vectoring, and cell engineering to in-vitro/in-vivo efficacy, IND authoring, and manufacturing support. Modular and GMP-aligned, the platform spans autologous and allogeneic routes (incl. TRAC/Cas9 and mRNA) to de-risk translation for hematologic and solid tumor programs.

End‑to‑end TCR‑like antibody services targeting peptide–MHC complexes—covering immunogen design, pMHC screening, affinity maturation, developability optimization, and functional validation—with output as IgG, bispecifics, or CAR constructs to access intracellular‑derived antigens.

End‑to‑end solid‑tumor CAR‑T development—from antigen/scFv discovery and CAR optimization to cell engineering, in‑vitro/in‑vivo efficacy, and IND support. Incorporates dual/logic‑gated and armored CARs, plus trafficking and persistence enhancements to overcome the tumor microenvironment and improve safety and translation.

End‑to‑end allogeneic cell therapy development—covering donor strategy, multiplex genome editing for safety/immune evasion, scalable manufacturing and comparability, and IND/CMC support—across CAR‑T/CAR‑NK and other donor‑derived modalities to enable off‑the‑shelf access.

Configurable TIL therapy development spanning tumor processing, TIL isolation/rapid expansion, functional and phenotypic qualification, and release criteria—paired with manufacturing‑aligned process development and IND documentation to de‑risk scale‑up for solid‑tumor programs.

A comprehensive collection of active, recombinant protein kinases, crucial for screening and profiling small molecule inhibitors and studying cellular signaling pathways in disease.

Proteins purified from their natural, endogenous sources, preserving post-translational modifications and complex native structures for biologically relevant research applications.

A service to identify the RNA targets of RNA-binding proteins (RBPs) on a genome-wide scale, providing insights into post-transcriptional regulatory networks.

Label-free, real-time analysis of biomolecular interactions to determine binding kinetics (kon, koff), affinity (KD), and specificity with high precision and sensitivity.

A specialized protein interaction screening service designed to identify interacting partners for membrane proteins, which are typically difficult to study with conventional Y2H.

Recombinant proteins specifically relevant as E3 ligases or target proteins for Proteolysis Targeting Chimeras (PROTACs), enabling the development of this novel targeted protein degradation technology.

A portfolio of recombinant immunoglobulins and cell surface proteins serving as critical targets for the development and functional validation of Chimeric Antigen Receptor T-cell (CAR-T) therapies.

A suite of analytical services, including SPR, BLI, and ITC, to quantitatively characterize the binding kinetics, affinity, and thermodynamics of biomolecular interactions.

Calculate drug toxicity and safety endpoints

Neurofilament light (NF-L) is a 68 kDa cytoskeletal intermediate filament protein that is expressed in neurons. It associates with the 125 kDa Neurofilament medium(NF-M) and the 200 kDa Neurofilament heavy (NF-H) to form neurofilaments. They are major components of the neuronal cytoskeleton, and are believed to function primarily to provide structural support for the axon and to regulate axon diameter. Neurofilaments can be re…

HD-X Analyzer

ARRALYZE 8 Chamber Slide combines standard slide format with advanced nanowell technology, featuring 8 chambers with 127 precisely etched nanowells (0.4 × 0.4 × 0.225mm) per chamber. The borosilicate glass bottom (0.175μm thick under wells) provides superior optical clarity for high-resolution imaging while maintaining an inert environment. Includes 3 fiducials per chamber for easy navigation and precise cell tracking.

Monoclonal Anti-Claudin-18.2 Antibody, Mouse IgG1 (3B10) was developed to be exquisitely CLDN18.2 specific, characterized as not cross-reacting with CLDN18.1 and without background staining.

In breast cancer STC2 is induced by estrogen and STC2 expression levels correlate with levels of estrogen receptor. STC2 function in different cancers may involve regulation of cell proliferation, neoplastic transformation and endothelial invasion. STC2 also plays a role in epithelial-mesenchymal transition by activation of MAPK/ERK signaling in hypoxic ovarian cancer cells. 

Svar specializes in creating cell-based Reporter Gene Assays with iLite® technology for a range of applications. This technology offers a precise, sensitive system with luciferase readout, suitable for testing drug activity, immunogenicity, and Fc-functional assays including CDC, ADCC, and ADCP activity. Svar's development capabilities cover nearly any pharmaceutical target, ensuring rapid and accurate assays.

Svar specializes in creating cell-based Reporter Gene Assays with iLite® technology for a range of complement applications. This technology offers a precise, sensitive system with luciferase readout, suitable for assessing drug activity for different targets such as C5a, and through Complement-Dependent Cytotoxicity (CDC) activity.

The iLite® C5a Assay Ready Cells can be used for the quantification of C5a activity, and for determination of inhibitory activity against either C5a itself or against the C5a receptor in test samples, including human serum.

With their proprietary technology, the iLite® technology Svar can develop Report Gene Assays – that area cleverly designed, sensitive and specific cell based reporter-gene system with luciferase readout. Svar can develop assays for virtually any pharmaceutical target that allow an easy, rapid and accurate test format for a wide range of applications, such as Immunogenicity and Potency assays.

The iLite® Functional Bioassay portfolio consists of cell lines provided in an “assay-ready” format for a rapid and convenient workflow. The assay-ready format also reduces assay variability, optimizing its use in screening, characterization, stability, and potency studies. iLite cell lines can be tailored to virtually any biopharmaceutical target.